Cargando…
A Systematic Literature Review on the Cost-Effectiveness of Apixaban for Stroke Prevention in Non-valvular Atrial Fibrillation
INTRODUCTION: Economic evaluations are becoming increasingly important due to limitations in economic resources, the expense of many new treatments, the need to allocate health spending as effectively as possible, and the need to inform decision makers. Based on the data from the apixaban studies (A...
Autores principales: | Pinyol, Carme, Cepeda, Jose Mª, Roldan, Inmaculada, Roldan, Vanesa, Jimenez, Silvia, Gonzalez, Paloma, Soto, Javier |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5125108/ https://www.ncbi.nlm.nih.gov/pubmed/27457613 http://dx.doi.org/10.1007/s40119-016-0066-2 |
Ejemplares similares
-
Cost-effectiveness of apixaban for stroke prevention in non-valvular atrial fibrillation in Saudi Arabia
por: Hersi, Ahmad S., et al.
Publicado: (2019) -
Economic Evaluation of Apixaban for the Prevention of Stroke in Non-Valvular Atrial Fibrillation in the Netherlands
por: Stevanović, Jelena, et al.
Publicado: (2014) -
Non-valvular atrial fibrillation: impact of apixaban on patient outcomes
por: Ioannou, Adam, et al.
Publicado: (2017) -
Real-world cost-effectiveness of rivaroxaban and apixaban vs VKA in stroke prevention in non-valvular atrial fibrillation in the UK
por: Bowrin, Kevin, et al.
Publicado: (2020) -
Cost-Effectiveness Analysis of Apixaban Versus Edoxaban in Patients with Atrial Fibrillation for Stroke Prevention
por: Oyagüez, Itziar, et al.
Publicado: (2019)